Tilray Brands Consolidates its Global Medical Offering into Tilray Medical, a Comprehensive Portfolio of Brands and Products – Yahoo Finance

Share Article

New Division Brings Together the Legacy Tilray and Aphria Medical Businesses; Includes Expanded Offerings in Canada
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced the launch of Tilray Medical, a global medical platform that unifies the Company's medical cannabis brands under one strategy, mission, and vision.

Denise Faltischek, Head of International and Chief Strategy Officer, said, "Tilray is the global leader in the advancement of cannabinoid-based medicine, with a focus on providing research-backed medical cannabis products to physicians, pharmacies, and patients. By unifying the global medical divisions of Tilray and Aphria under a cohesive strategy and mission, Tilray Medical emerges as the premier global supplier of a portfolio of high-quality, effective medical cannabis brands and products for patients in need around the world."
Under the Tilray Medical consolidation plan, patients in Canada will have the broadest access to our medical cannabis brands and product choices globally, including Tilray, Aphria, Broken Coast, and Symbios. Subject to local regulatory approvals, Tilray Medical's global portfolio of medical cannabis products includes high-quality and GMP-certified flower, oils, vapes, edibles, and topicals. Looking ahead, Tilray Medical will continue to expand its offering to patients worldwide.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Canada, Tilray Medical Australia, Tilray Medical Australia-New Zealand, Tilray Medical Europe
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body, and soul while invoking wellbeing. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing, visit www.Tilray.com.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients worldwide, including via Tilray Medical . Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Contacts:
Tilray Brands:
Berrin Noorata
[email protected]
Investors
Raphael Gross
203-682-8253
[email protected]

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the Florida launch of two proprietary brands, Sweet Talk™ and Momenta™, new Cultivar Collection™ flower releases, and the second product drop of Live Diamonds by Muse™.
Penn missed fourth-quarter earnings estimates but topped revenue projections amid tough competition. Is PENN stock a buy?
Tilray Inc. said Tuesday it created its new Tilray Medical unit by combining the medical divisions of Tilray and Aphria. The move comes after Tilray acquired Aphria in May, 2021. "By unifying the global medical divisions of Tilray and Aphria under a cohesive strategy and mission, Tilray Medical emerges as the premier global supplier of a portfolio of high-quality, effective medical cannabis brands and products for patients in need around the world," said Denise Faltischek, head of international
Tilray stock has fallen since the Canadian pot producer reported earnings. Should you buy TLRY stock now?
After suffering a historic rout in its share price, Mark Zuckerberg's social media group warns it may be forced to forfeit up to a quarter of its revenue.
Shares of Facebook parent Meta Platforms (NASDAQ: FB) fell 5.1% on Monday amid a clash with European regulators. The European Union's data watchdogs want to better protect its citizens' personal information. Meta Platforms' stock price fell sharply on Monday.
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
Shares of Meta Platforms (NASDAQ: FB) were sliding once again today as investors continued to process comments made by the company recently that indicated that Meta could potentially shut down Facebook and Instagram in Europe due to increasing regulations. European regulators are working on a law that could potentially prohibit companies from sending Europeans' data across the Atlantic to the U.S. Meta said late last week that such a move could force the company to shut down Facebook and Instagram in the region. In addition to Meta's precarious position in Europe, the company also announced yesterday that Peter Thiel, a member of Meta's board of directors since 2005, has decided not to stand for reelection.
Shares of Asana (NYSE: ASAN) are making big gains in today's trading. The company's share price was up roughly 10% in the daily session as of 2 p.m. ET Tuesday. Meanwhile, the Nasdaq Composite index was up approximately 1%, and the S&P 500 index was up roughly 0.7%.
Shares rose after a bad day yesterday, as well as reports that Chinese state-backed funds began buying local stocks.
As of 1:55 p.m. ET, shares of Rivian stock were up by a solid 3% — but investors shouldn't let that fact make them complacent. Turns out, there's some disturbing news about Rivian afoot, and while it's not getting a whole lot of press yet, it does bear watching. As the Normal Fire Department explained in a press release:  "Normal Firefighters were called to the Rivian Automotive Plant at 100 N. Rivian Motorway just after 9 p.m. for the report of a vehicle on fire inside the building."
The stock markets have started off 2022 with increased volatility, and that’s opened up opportunities for investors – especially for investors willing to shoulder some additional risk. The sharp decline in January lowered prices, while the rapid swings we’ve seen in recent trading sessions makes it possible to take advantage of the lowered entry point. A market situation like this should naturally bring investors’ attention to the penny stocks. These low-cost equities, typically priced below $5
Yahoo Finance Live's Julie Hyman discusses the recent stock surge in sensor maker Velodyne after Amazon invests in the company.
Biotech stocks are going through a historic drawdown at the moment. Nearly 400 publicly traded biotech companies have lost 40% or more of their value in just the past six months. Many of these beaten-down biotech stocks will ultimately rebound.
Yahoo Finance's Jared Blikre breaks down Lyft's most recent quarterly earnings.
It might be tempting to be a hero and buy crashing S&P 500 stocks. But it's a risky move that might leave you holding the bag.
Not surprisingly, online retail spending is expected to grow at nearly 11% per year through 2025, reaching $7.4 trillion, according to eMarketer. Not surprisingly, Shopify has consistently posted stellar financial results. Over the past year, revenue soared 71% to $4.2 billion, gross margin expanded 150 basis points to 54.5%, and free cash flow rocketed 150% higher to $458.2 million.
Advanced Micro Devices (NASDAQ: AMD) had a forgetful start to the year as shares of the chipmaker plunged close to 21% last month, but it hasn't taken long for the company to regain its mojo on the stock market. AMD stock has recovered a lot of ground over the past few days, aided by a solid fourth-quarter earnings report that handsomely crushed expectations. What's more, the company's 2022 guidance indicates that it is on track to deliver another year of solid growth, which has prompted Wall Street analysts to raise their expectations for AMD stock.
Few companies have the stability at the top that Costco does. CEO Craig Jelinek has held the position since 2012 and had a long run with the company before he ascended to the top job. CFO Richard Galanti, who leads the company's earnings calls, has held his job even longer.
How far off is Micron Technology, Inc. ( NASDAQ:MU ) from its intrinsic value? Using the most recent financial data…

source

You might also like

Surviving 2nd wave of corona
COVID-19

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort

@voguewellness